NovaBay Pharmaceuticals, Inc. (NBY)
USD 0.49
(-9.24%)
USD 0.49
(-9.24%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 5.72 Million USD | -2.14% |
| 2022 | 5.84 Million USD | -57.67% |
| 2021 | 13.8 Million USD | 372.84% |
| 2020 | 2.92 Million USD | -71.5% |
| 2019 | 10.24 Million USD | 132.52% |
| 2018 | 4.4 Million USD | -41.12% |
| 2017 | 7.48 Million USD | -9.6% |
| 2016 | 8.28 Million USD | -18.62% |
| 2015 | 10.17 Million USD | 78.85% |
| 2014 | 5.68 Million USD | -20.26% |
| 2013 | 7.13 Million USD | 37.56% |
| 2012 | 5.18 Million USD | -21.65% |
| 2011 | 6.61 Million USD | 31.7% |
| 2010 | 5.02 Million USD | 20.3% |
| 2009 | 4.17 Million USD | -36.93% |
| 2008 | 6.62 Million USD | -31.01% |
| 2007 | 9.6 Million USD | -4.49% |
| 2006 | 10.05 Million USD | 3142.9% |
| 2005 | 310 Thousand USD | 0.0% |
| 2003 | 513 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 4.54 Million USD | -12.6% |
| 2024 Q1 | 5.19 Million USD | -9.14% |
| 2023 Q1 | 5.93 Million USD | 1.54% |
| 2023 Q3 | 5.81 Million USD | -21.89% |
| 2023 Q2 | 7.44 Million USD | 25.44% |
| 2023 Q4 | 5.72 Million USD | -1.63% |
| 2023 FY | 5.72 Million USD | -2.14% |
| 2022 Q2 | 5.79 Million USD | -17.72% |
| 2022 Q3 | 8.59 Million USD | 48.16% |
| 2022 FY | 5.84 Million USD | -57.67% |
| 2022 Q4 | 5.84 Million USD | -31.97% |
| 2022 Q1 | 7.04 Million USD | -48.95% |
| 2021 Q4 | 13.8 Million USD | 380.24% |
| 2021 FY | 13.8 Million USD | 372.84% |
| 2021 Q1 | 3.08 Million USD | 5.79% |
| 2021 Q2 | 2.39 Million USD | -22.5% |
| 2021 Q3 | 2.87 Million USD | 20.09% |
| 2020 FY | 2.92 Million USD | -71.5% |
| 2020 Q3 | 3.2 Million USD | -73.96% |
| 2020 Q2 | 12.28 Million USD | 25.09% |
| 2020 Q1 | 9.82 Million USD | -4.13% |
| 2020 Q4 | 2.92 Million USD | -8.75% |
| 2019 FY | 10.24 Million USD | 132.52% |
| 2019 Q1 | 9.38 Million USD | 112.84% |
| 2019 Q2 | 8.2 Million USD | -12.57% |
| 2019 Q3 | 11.68 Million USD | 42.42% |
| 2019 Q4 | 10.24 Million USD | -12.27% |
| 2018 Q3 | 4.3 Million USD | 0.7% |
| 2018 FY | 4.4 Million USD | -41.12% |
| 2018 Q4 | 4.4 Million USD | 2.35% |
| 2018 Q2 | 4.27 Million USD | -13.65% |
| 2018 Q1 | 4.95 Million USD | -33.84% |
| 2017 Q3 | 9.22 Million USD | 4.1% |
| 2017 Q4 | 7.48 Million USD | -18.85% |
| 2017 Q2 | 8.86 Million USD | 6.43% |
| 2017 Q1 | 8.32 Million USD | 0.56% |
| 2017 FY | 7.48 Million USD | -9.6% |
| 2016 Q4 | 8.28 Million USD | -1.7% |
| 2016 Q1 | 12.23 Million USD | 20.2% |
| 2016 Q2 | 9.47 Million USD | -22.55% |
| 2016 Q3 | 8.42 Million USD | -11.07% |
| 2016 FY | 8.28 Million USD | -18.62% |
| 2015 FY | 10.17 Million USD | 78.85% |
| 2015 Q1 | 6 Million USD | 5.57% |
| 2015 Q2 | 5.27 Million USD | -12.25% |
| 2015 Q3 | 6.46 Million USD | 22.64% |
| 2015 Q4 | 10.17 Million USD | 57.43% |
| 2014 Q3 | 5.35 Million USD | 24.69% |
| 2014 Q4 | 5.68 Million USD | 6.28% |
| 2014 Q2 | 4.29 Million USD | -19.74% |
| 2014 Q1 | 5.34 Million USD | -25.02% |
| 2014 FY | 5.68 Million USD | -20.26% |
| 2013 Q2 | 5.61 Million USD | 10.59% |
| 2013 Q1 | 5.07 Million USD | -2.06% |
| 2013 Q4 | 7.13 Million USD | 4.56% |
| 2013 FY | 7.13 Million USD | 37.56% |
| 2013 Q3 | 6.82 Million USD | 21.47% |
| 2012 FY | 5.18 Million USD | -21.65% |
| 2012 Q1 | 6.67 Million USD | 0.83% |
| 2012 Q4 | 5.18 Million USD | -16.7% |
| 2012 Q3 | 6.22 Million USD | -3.64% |
| 2012 Q2 | 6.46 Million USD | -3.19% |
| 2011 Q3 | 5.35 Million USD | -0.76% |
| 2011 Q2 | 5.39 Million USD | -5.69% |
| 2011 FY | 6.61 Million USD | 31.7% |
| 2011 Q1 | 5.72 Million USD | 13.91% |
| 2011 Q4 | 6.61 Million USD | 23.53% |
| 2010 Q1 | 3.98 Million USD | -4.72% |
| 2010 Q2 | 2.35 Million USD | -40.79% |
| 2010 Q3 | 3.13 Million USD | 33.05% |
| 2010 Q4 | 5.02 Million USD | 60.27% |
| 2010 FY | 5.02 Million USD | 20.3% |
| 2009 Q2 | 5.57 Million USD | -25.26% |
| 2009 FY | 4.17 Million USD | -36.93% |
| 2009 Q1 | 7.45 Million USD | 12.58% |
| 2009 Q3 | 5.65 Million USD | 1.45% |
| 2009 Q4 | 4.17 Million USD | -26.11% |
| 2008 FY | 6.62 Million USD | -31.01% |
| 2008 Q1 | 10.34 Million USD | 7.75% |
| 2008 Q2 | 9.24 Million USD | -10.62% |
| 2008 Q3 | 8.79 Million USD | -4.9% |
| 2008 Q4 | 6.62 Million USD | -24.68% |
| 2007 Q3 | 10.74 Million USD | 4.94% |
| 2007 Q1 | 10.79 Million USD | 7.39% |
| 2007 FY | 9.6 Million USD | -4.49% |
| 2007 Q4 | 9.6 Million USD | -10.67% |
| 2007 Q2 | 10.24 Million USD | -5.12% |
| 2006 FY | 10.05 Million USD | 3142.9% |
| 2006 Q4 | 10.05 Million USD | 0.0% |
| 2005 FY | 310 Thousand USD | 0.0% |
| 2005 Q4 | 310 Thousand USD | 0.0% |
| 2003 FY | 513 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 9.14 Million USD | 37.466% |
| Ampio Pharmaceuticals, Inc. | 2.37 Million USD | -140.741% |
| Armata Pharmaceuticals, Inc. | 142.02 Million USD | 95.973% |
| Actinium Pharmaceuticals, Inc. | 45.06 Million USD | 87.308% |
| Azitra, Inc. | 2.2 Million USD | -159.724% |
| Can-Fite BioPharma Ltd. | 3.74 Million USD | -52.696% |
| Chromocell Therapeutics Corporation | 6.54 Million USD | 12.551% |
| Calidi Biotherapeutics, Inc. | 18.25 Million USD | 68.664% |
| CEL-SCI Corporation | 17.31 Million USD | 66.962% |
| iBio, Inc. | 7.41 Million USD | 22.807% |
| Lineage Cell Therapeutics, Inc. | 38.99 Million USD | 85.332% |
| MAIA Biotechnology, Inc. | 7.08 Million USD | 19.315% |
| Matinas BioPharma Holdings, Inc. | 46.33 Million USD | 87.654% |
| Navidea Biopharmaceuticals, Inc. | 12.51 Million USD | 54.295% |
| NanoViricides, Inc. | 1.35 Million USD | -320.967% |
| Oragenics, Inc. | 1.79 Million USD | -218.099% |
| BiomX Inc. | 55.07 Million USD | 89.614% |
| BiomX Inc. | 55.07 Million USD | 89.614% |
| Protalix BioTherapeutics, Inc. | 50.86 Million USD | 88.755% |
| Palatin Technologies, Inc. | 10.85 Million USD | 47.299% |
| Scorpius Holdings, Inc. | 22.74 Million USD | 74.85% |